# Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

> **NCT03150160** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** brinzolamide 1%/brimonidine 0.2% fixed combination
- **DRUG:** Placebo
- **DRUG:** travoprost 0.004% ophthalmic solution

## Key facts

- **NCT ID:** NCT03150160
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-21
- **Primary completion:** 2017-12-04
- **Final completion:** 2017-12-04
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2019-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150160, "Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03150160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*